Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D08PKI
|
||||
| Former ID |
DIB012872
|
||||
| Drug Name |
EV-077
|
||||
| Synonyms |
EV-077-3201; EV-077 series (diabetes), Evolva Biotech; EV-077-3201-2; EV-077-3201-2TBS; Thromboxane antagonist (cardiovascular/proteinuric renal disease), Evolva Holding; Thromboxane synthesis inhibitor (cardiovascular/ proteinuric renal disease), Evolva Holding; EV-0400 series (metabolic disease/diabetes), Evolva Biotech; PPAR-gamma agonists (metabolic disease/diabetes/proteinuric renal disease/cardiovascular), Evolva Biotech
|
||||
| Indication | Type 2 diabetes [ICD9: 250; ICD10:E11] | Phase 2 | [523832] | ||
| Company |
Evolva SA
|
||||
| Target and Pathway | |||||
| Target(s) | Thromboxane-A synthase | Target Info | Modulator | ||
| BioCyc Pathway | C20 prostanoid biosynthesis | ||||
| PathWhiz Pathway | Arachidonic Acid Metabolism | ||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.